Loading
A phase 1/2 trial of Tozuleristide run by University of Washington, terminated.
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery is a phase 1/2 interventional study registered as NCT05316688 by University of Washington, with 8 participants enrolled, started 2024-04-17. Conditions recorded: Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8 and Stage IVA Lip and Oral Cavity Cancer AJCC v8. Interventions recorded: Near Infrared Imaging, Therapeutic Conventional Surgery and Tozuleristide.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Tozuleristide, Blaze Bioscience and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/